Michael H. Davidson
ORCID: 0000-0001-9342-1274Also affiliated with Kiadis Pharma (Netherlands)
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 5 papers. Top paper: “Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial”.
Michael H. Davidson, Prediman K. Shah, Charles W. Stark, Wenqi Lu, Cheerag Shirodaria +5 more
Distinct genetic liability profiles define clinically relevant patient strata across common diseases
Georgii Dolgalev, Sylvain Moser, Laura T. Jiménez-Barrón, Till F. M. Andlauer, Moritz von Scheidt +95 more
Andrew Hsieh, John J.P. Kastelein, Michael H. Davidson
Patrick Sun, Zane A. Maggio, Marc Ditmarsch, John J.P. Kastelein, Michael H. Davidson +1 more
Patrick Sun, Marc Ditmarsch, John J.P. Kastelein, Michael H. Davidson, Bohdan B. Khomtchouk